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Abstract 
Purpose and Background: Motion mitigation during prostate stereotactic body radiation 
therapy (SBRT) ensures optimal target coverage while reducing the risk of overdosage of 
nearby organs. The geometrical and dosimetrical performance of motion mitigation with the 
multileaf-collimator (MLC tracking) or the treatment couch (couch tracking) were compared. 
Material and Methods: For ten prostate patients, SBRT treatment plans with integrated 
boosts were prepared using volumetric modulated arc technique. For the geometrical 
evaluation, a lead sphere at the beam isocenter was moved according to five prostate motion 
curves (i) without mitigation, (ii) with MLC tracking or (iii) with couch tracking. During irradiation, 
MV images were taken and the over-/underexposed areas were evaluated. 
For the dosimetrical evaluation, the plans were applied to a dosimetric phantom. Dose 
distributions with and without mitigation were evaluated inside the target structure and organs 
at risk. 
Results: The median over-/underexposed area was reduced significantly from 2.02 cm2 
without mitigation to 1.00 cm2 and 0.45 cm2 with MLC and couch tracking. Closest dosimetrical 
agreement to the static references was achieved with couch tracking.  
Conclusions: MLC and couch tracking at a conventional linear accelerator significantly 
improved the accuracy of prostate SBRT in the presence of motion, whereby couch tracking 
showed slightly better performance than MLC tracking.  
3 
 
Introduction 
Active motion mitigation during radiotherapy treatments of moving targets can be used to 
reduce the high-dose treatment volume and thereby spare the healthy tissue. Stereotactic 
body radiation therapy (SBRT) has been shown to be an effective treatment for localised 
prostate cancer [1], however it could further profit from on-line motion mitigation. First, the 
prostate shows systematic and erratic motion which can reach up to 10 mm [2, 3, 4]. This 
motion is conventionally considered by increasing the target volume with a safety margin, but 
this simultaneously increases the dose to the adjacent organs. With on-line motion mitigation 
throughout the treatment, this margin could be reduced. Second, SBRT aims to deliver high 
target doses with steep dose gradients in only a few treatment fractions. To maximally exploit 
SBRT, high accuracy in dose delivery is required. 
On-line motion mitigation can be performed at a conventional linear accelerator either by 
following the target motion with the treatment field through constant adaptation of the multileaf-
collimator (MLC tracking [5, 6]), or by counter-movement of the patient with the treatment 
couch according to the target motion (couch tracking [7, 8]).  
Studies on prostate treatment improvement have been performed for MLC tracking [9, 10] and 
couch tracking [11]. Moreover, both have been compared in a few studies. A multi-institutional 
study [12] compared real-time adaptive therapy with robotic, gimbaled, MLC and couch 
tracking. The four modalities were found to perform similarly. Other studies [13, 14] compared 
MLC and couch tracking directly for prostatic motion traces. They found better motion 
mitigation for couch tracking, especially for high-modulated treatment plans [13].  
These studies focused their evaluation on the target dose distribution of a few treatment plans 
with a homogeneous dose prescription. For an extensive comparison of MLC and couch 
tracking, we included dosimetry of the nearby organs, a two level dose prescription and a larger 
patient cohort in combination with various distinct motion trajectories. 
Material and Methods 
Treatment planning 
For ten prostate cancer patients, SBRT treatment plans with integrated boost to the index 
lesion were generated as described in Ehrbar et al. [11] using volumetric-modulated arc 
therapy (VMAT). A mean dose of 5 x 8 Gy = 40 Gy was prescribed to the planning target 
volume (PTV) around the index lesion (PTVindex = index lesion plus 3-mm margin), and a lower 
dose of 5 x 7 Gy = 35 Gy to the PTV around the prostate (PTVprostate = prostate plus 5 mm). 
Rectum, bladder and urethra were contoured as organs at risk (OAR). The rectum, bladder 
and urethra maximum dose (D0.1cc) was restricted to 36.25 Gy and the distal rectum wall to 
maximal 35 Gy. To test whether the tracking performance also depends on the MLC 
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orientation, two treatment plans were created for each patient, one with collimator rotations 
around 0° (range: 350°-10°) and one with 90° (80°-100°).  
Motion traces 
Five prostate motion traces were selected to show a variety of possible prostate displacements 
during radiotherapy treatments (see Ehrbar et al. [11] for details). These traces were recorded 
by Ehrbar et al. [11] (Trace 1) and Langen et al. [13] (Trace 2-5). The used sections of the 
traces are shown in Figure 1 together with the temporal displacement fraction and mean offset 
for each motion trace. 
MLC and couch tracking 
Active motion mitigation with MLC or couch tracking was performed at a TrueBeam 2.0 linear 
accelerator (Varian Medical Systems, Inc., Palo Alto CA, USA). The TrueBeam was equipped 
with the High Definition 120 Leaf MLC and the PerfectPitch treatment couch. The system was 
employed in developer mode using the iTools-Tracking platform. This platform links the real-
time position information of the target with the supervisor, which controls the MLC or couch 
position during the treatment. The position of the moving target was monitored with Calypso 
radiofrequency transponders (Varian Medical Systems, Inc., Palo Alto CA, USA) at a rate of 
25 Hz and transferred to the iTools-Tracking software. A linear Kalman prediction filter is 
applied to the signal. For ongoing target motion, this filter is able to partially compensate for 
latencies caused by the time required for signal detection, signal processing and treatment 
adaptation. The predicted target displacement is then compensated with adaptation of the 
treatment field via the MLC or with counter-movement of the target via the treatment couch. 
The same tracking system was previously presented by Ehrbar et al. for couch tracking of lung 
tumors [15] and prostate tumors [11], and a similar system from the same vendor was studied 
by Hansen et al. [13] for MLC and couch tracking. 
Geometrical performance 
The geometrical performance of MLC and couch tracking was evaluated using mega-voltage 
(MV) fluoroscopy of a moving target. The target, a lead sphere with 10 mm diameter, was 
placed in the beam isocenter and moved in three dimensions with the HexaMotion stage 
(ScandiDos, Uppsala, Sweden). For position feedback, two Calypso transponders were placed 
on the lead sphere mount outside the treatment field. The twenty treatment plans were applied 
to the target and MV images were taken continuously at a rate of  7.7 Hz. These images show 
the lead sphere in respect to the MLC shaped field edges at different angular positions 
throughout the treatment. Each treatment plan was applied 16 times. First, one MV-image set 
was taken with the target in static position. This was used as the reference situation. Second, 
15 MV-image sets were taken while the target was moved according to the five prostate motion 
traces during irradiation and with three modes of motion mitigation: no mitigation, MLC or 
couch tracking. The lead sphere was detected in each image with a template matching 
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algorithm (see Figure 2). The images were centered at the position of the lead sphere and a 
threshold was applied to create binary images. By comparison with the reference image at the 
same gantry angle, over- and underexposed areas at the field edges could be determined. 
This shows how well the motion was mitigated with MLC or couch tracking, since the relation 
between the lead sphere and the field edges should be the same for reference images and 
perfectly tracked images. Each measurement was quantified with the mean over-
/underexposed area (?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒) by averaging over the overexposed and underexposed areas 
of all images evaluated per MV image set. 
Since the MV images were not taken exactly at the same gantry angles, the image sets were 
interpolated to every 1° of the treatment arc and only these interpolated images were taken 
into the evaluation. VMAT plans are highly modulated and might block the view of the lead 
sphere. Therefore, the MLC leafs of the treatment plan were artificially retracted by 60 mm. 
The artificially enlarged area was removed from the evaluation during image post-processing.  
The reproducibility of the geometric measurement and evaluation algorithm was tested by 
comparing four repeated static measurements of patient 10 against the initial static 
measurement. Two reproducibility measurements were taken right after the initial static 
measurement and before the acquisition of mitigated measurements (pre-acquisition), while 
the other two reproducibility measurements were taken after all mitigated measurements (post-
acquisition). The ?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 of the pre- and post-acquisition reproducibility measurements, 
compared to the initial static measurements, were calculated. 
Dosimetrical performance 
The dosimetrical performance of MLC and couch tracking was evaluated using phantom 
measurements. The treatment plans were delivered to the Delta4 phantom (ScandiDos, 
Uppsala, Sweden), which was mounted on the HexaMotion stage. For each treatment plan, 
16 measurements were taken. First, one dose measurement was taken with the target in static 
position. This was used as reference situation. Second, 15 measurements were taken while 
the phantom was moved according to the five prostate motion traces during irradiation and 
with three modes of motion mitigation: no mitigation, MLC or couch tracking. The dose was 
measured in a biplanar array within the phantom and backprojected over the whole phantom 
using depth-dose curves. The patient’s anatomical contours were overlayed to this dose 
distribution and dose parameters were compared against the static references. Gamma 
agreement indices (GAI) with 1%/1 mm and 2%/2 mm pass criterion were evaluated within the 
entire phantom, the target structures (index lesion and prostate) and the OARs (rectum, 
urethra, bladder). Global dose differences were used with the 100% dose level set at the 
maximum dose of the treatment plan, and only doses above 20% were taken into the gamma 
evaluation. For the target structures, the deviations in the mean dose (Dmean) and in the dose 
covering 95% of the volume (D95) were evaluated. For the OARs, the deviations in the 
6 
 
maximal dose (Dmax) were evaluated. For this organ specific evaluations, the research 
version 1.00.0103c of the Delta4 dose evaluation software was used together with the Delta4DVH 
function. 
Data evaluation and statistics 
The mean over-/underexposed area (?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒) and the phantom GAI2%/2mm were separately 
evaluated for all traces and collimator rotations. For the organ specific evaluations, the results 
of all measurements per mitigation mode were grouped together. Comparisons between 
collimator rotations or between mitigation modes were performed with a paired Wilcoxon 
signed rank test, while mitigation modes were compared with a multi-sample Friedman’s test 
beforehand. The equality of variance was tested with multi-sample Brown Forsythe test, 
performing an ANOVA on absolute deviations of the data values from their group medians. 
This was done for the dose parameters only (Dmean, D95 and Dmax). Correlations between 
the geometrical and dosimetrical performance were evaluated with Spearman rank correlation 
coefficients (Rho). The significance level was set at 5% for all tests (p<0.05, for p-values 
multiplied with Bonferroni correction).  
Results 
Geometrical performance 
Over all traces and collimator rotations, the median ?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 was reduced significantly from 
2.02 cm2 (quartiles: 1.55 cm2, 2.51 cm2) without motion mitigation to 1.00 cm2 (0.77 cm2, 1.21 
cm2) and 0.45 cm2 (0.40 cm2, 0.54 cm2) with MLC and couch tracking, respectively. Figure 3A 
shows the ?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 separately for each motion trace, collimator rotation and mitigation mode. 
For the stable prostate (trace 5) all mitigation modes showed similar values. For all mitigation 
modes, the plans with 90° collimator rotation showed lower median ?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 than 0°. This 
difference was significant for no mitigation (-0.33 cm2) and couch tracking (-0.04 cm2), but not 
for MLC tracking (-0.12 cm2). 
For the two pre-acquisition reproducibility measurements, ?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 of 0.11 cm2 and 0.16 cm2 
were found, and 0.24 cm2 and 0.29 cm2 for post-acquisition. For comparison, the median field 
openings per patient and arc were evaluated and ranged from 11.47 cm2 to 26.27 cm2 with a 
mean of 18.30 cm2. 
Dosimetrical performance 
Over all traces and collimator rotations, the median phantom GAI2%/2mm was improved 
significantly from 83.9% (quartiles: 77.0%, 94.1%) without motion mitigation to 98.6% (96.3%, 
99.7%) and 100.0% (100.0%, 100.0%) with MLC and couch tracking, respectively. Figure 3B 
shows the GAI2%/2mm separately for each motion trace, collimator rotation and mitigation mode. 
For all mitigation modes, the plans with 90° collimator rotation showed a better median 
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GAI2%/2mm than 0°. This difference was significant for all, possibly relevant for no mitigation 
(+4.1%) and MLC tracking (+2.2%), but irrelevant for couch tracking (+0.0%). 
The structure specific GAI and changes in dose parameters are shown in Figure 4. The 
corresponding values are presented in Table 1 and comparisons between mitigation modes in 
Table 2. Overall, both tracking concepts resulted in better coverage of the target volumes and 
better agreement of the OAR doses than no mitigation. While the index lesion and prostate 
Dmean were significantly decreased without mitigation (median: -0.64% and -0.17%, 
respectively), Dmean showed a small difference to the static situation with couch tracking 
(+0.11% and +0.09%) and significantly increased values with MLC tracking (+0.22% and 
+0.49%). For the rectum and bladder, there was no significant difference found in Dmax 
between the mitigation modes, but the spread in the data was reduced with MLC and couch 
tracking. For the urethra, Dmax was significantly higher for MLC tracking (+1.05%) than couch 
tracking (+0.33%).  
Over all parameters, the geometrical ?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 was highly correlated (absolute Rho > 0.75) with 
the phantom, prostate, rectum, urethra and bladder GAI1%/1mm, and the phantom, prostate and 
urethra GAI2%/2mm. The changes in dose parameters (ΔDmean, ΔD95 and ΔDmax) on the other 
hand showed only weak or no correlations with ?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 (details see Table 2). But the variance 
of these dose parameters could be significantly reduced with couch tracking in all cases and 
with MLC tracking in most cases (see Table 3). 
Discussion 
Couch tracking and MLC tracking, two motion mitigation techniques at a conventional linear 
accelerator, were directly compared in this study. Both tracking concepts were able to improve 
the geometrical and dosimetrical accuracy of prostate SBRT in the presence of motion. The 
overall and organ specific evaluations showed good agreement with the static reference 
conditions for both mitigation techniques, with slightly better agreement for couch tracking. 
For the geometrical evaluation, clinical treatment plans with realistic MLC modulation were 
used. The results showed significantly lower mean over- and underexposed area for couch 
tracking than MLC tracking (see Figure 3). Hansen et al. [13] performed a similar geometrical 
comparison, but used spherical field shapes without modulation. They showed better 
compensation with MLC tracking than couch tracking, except for small motions perpendicular 
to the MLC. This differential outcome might be explained by the missing MLC modulation in 
the simple spherical field: In modulated fields, more MLC leafs reach inside the open field than 
in a spherical field. The MLC tracking perpendicular to these MLC leafs is restricted due to the 
finite leaf width and their binary character. The MLC tracking error caused by the perpendicular 
motion component is therefore assumed to be larger for modulated fields with more complex 
field shapes. Additionally, the prostate motion traces show substantial motion in more than one 
direction, always resulting in a substantial motion component perpendicular to the leafs which 
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cannot be fully compensated. This might also explain why there was no relevant difference 
found between the two collimator rotations of 0° and 90°. However, Murtaza et al. [16] showed 
a reduced MLC tracking error for rotating collimator VMAT treatments, where the rotating 
collimator aligns the MLC leafs with the population-based dominant motion direction.  
A further restriction of the investigated MLC tracking system might be its restricted maximum 
leaf speed of 25 mm/s. The MLC has two tasks, the dose modulation and the motion mitigation. 
By fulfilling both tasks simultaneously, the MLC might reach its physical restrictions. This could 
be solved by introducing a restriction in the maximum allowed MLC speed during treatment 
plan optimization. 
The two tracking systems have different motion restrictions and therefore different tracking 
latencies. Those were reported by Hansen et al. [13] to be 146 ms for MLC tracking and 187 
to 246 ms for couch tracking (depending on the period of a sinusoidal motion). These latencies 
are in the same range and might not influence the dosimetric results. Also due to the use of 
prediction filters, the dependence on the system latency might have been reduced.  
Dosimetrically, the gamma agreement over the whole phantom with a 2%/2-mm criterion was 
improved from median 83.9% without mitigation to 98.6% with MLC tracking and to 100.0% 
with couch tracking. Better dosimetric performance of couch tracking over MLC tracking has 
previously been shown. Menten et al. [14] showed with film measurements for prostate step-
and-shoot IMRT a gamma agreement (2%/2 mm) of 60.1% without compensation, 85.0% with 
MLC tracking and 95.3% with couch tracking. Hansen et al. [13] also showed for a high 
modulated prostate plan a better dosimetrical performance of couch tracking (failure rate: 
0.1%) compared to MLC tracking (15.5%). The performance of MLC tracking in the present 
study was closer to couch tracking than in these previous studies. This might possibly be 
caused by different prediction filters and control loops, or by the thinner leaf width used in our 
study of only 2.5 mm compared to 5 mm.  
The organ specific evaluation (see Figure 4 and Table 1), showed that underdosage of the 
target volume and overdosage of the organs at risk can be mitigated successfully with tracking. 
Couch tracking showed very close agreement to the static reference measurements for all GAI 
and dose parameters. MLC tracking showed slightly worse agreement. Concretely, a dose 
increase  above the static values was found for the target structures with MLC tracking. This 
increased target dose also resulted in increased urethra Dmax and explains the worse target 
and urethra GAI1%/1mm for MLC tracking than couch tracking. The cause for these increased 
target doses is ambiguous. Probably, the field openings were increased during MLC tracking 
or the shifts of the field opening against the beam profile might have altered the actual photon 
fluence.  
The geometrical performance agrees well with the gamma evaluations of the dosimetrical 
measurements (see correlations Table 2). However, the geometrical measure does not 
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satisfactorily correlate with the changes in the other dosimetrical parameters as changes in 
Dmean, D95 and Dmax. These low correlations might be explained by the dependence of 
these parameters on the motion direction rather than the total amount of target offset alone. 
Also the median changes in Dmax did not differ significantly. However, we showed that the 
variance of these parameters was significantly reduced with tracking and therefore tracking 
would benefit the overall patient cohort by minimizing the dose offset from the planned dose 
distribution. 
The measurement reproducibility of the dosimetric evaluation was previously evaluated [11]. 
Repeated measurements showed perfect agreement with a 1%/1-mm gamma criterion. It was 
also shown that the Calypso system has no considerable influence on the dose measurement. 
To approximate the accuracy of the geometric measurements, the reproducibility was tested 
with five repeated static measurements showing an ?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 of 0.11 cm2 to 0.29 cm2 (0.5% to 
1.3%, in respect to the median field opening). These discrepancies might have been caused 
by the angle-wise interpolation of the fields or by inaccuracies of beam delivery itself. The 
geometric evaluations are assumed to be more sensitive to target offset, since every under-
/overexposed pixel (0.021x0.021 cm2) of each interpolated image is taken into consideration 
and not only the overall dosimetric effect. Generally, an  ?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 below 0.90 cm2 showed 
GAI2%/2mm above 95%. 
The accuracy of the dosimetric evaluation depends directly on the accuracy of the Delta4 dose 
measurement and its 3D interpolated dose. Latter has been validated with film measurements 
[17], ion chamber measurements [18] and a rotating phantom arrangement [19]. All three 
studies showed good agreement of the 3D interpolated dose with the independently measured 
dose and the planned dose. Furthermore, to exclude inaccuracies of dose calculation 
algorithms and measurement limitation from the tracking inaccuracies, comparisons were 
performed against measured dose distributions in static setup instead of the planned dose 
distributions. 
In this study, only rigid motion of the prostate and the surrounding organs was assumed. For 
a more sophisticated evaluation regarding deforming tissues, either anthropomorphic 
dosimetric phantoms, which can perform realistic deformations, or dose reconstructions using 
four-dimensional image information are required. Latter could be realized with MRI-guided 
radiotherapy units, where continuous imaging information can be employed to reconstruct the 
dose to moving and deforming organs as proposed by Glitzner et al. [20]. The dynamic change 
of the beam (MLC tracking) or patient position (couch tracking) could easily be included into 
this dose accumulation workflow. Real-time 4D dose reconstruction for MLC tracking have 
been proposed [21, 22], but without including real-time images as calculation basis yet.  
MLC and couch tracking can also be employed to compensate for respiratory motion, which 
has a different dynamic behavior than prostatic motion. On a dosimetric level, both tracking 
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techniques have been found to perform similarly for lung traces and improved the dose 
deposition accuracy when compared to no mitigation [13, 14]. 
The possibility of a hybrid couch-MLC tracking has been investigated by Toftegaard et al. [23] 
in a simulation study. A combination of both techniques would further improve the accuracy, 
when compared to pure MLC tracking, and simultaneously reduce the acceleration and jerk 
applied to the patient by the treatment couch, compared to pure couch tracking.  
The results of this comparison study are valid for the presented MLC and couch tracking 
systems. The performance of couch and MLC tracking is generally limited by the accuracy of 
the motion signal, the system latency, the effectiveness of the prediction filter and hardware 
restrictions such as maximal speed and acceleration of the couch or MLC leafs and the MLC 
leaf width. Developments in these domains could further improve the tracking performance. A 
different tracking implementation might therefore change the results of this experiment. 
To make tracking safely applicable in clinics, further work should be invested in quality 
assurance protocols, robustness analyses and the evaluation of inverse interplay effects of 
nearby organs which do not move according to the target structures. 
Conclusion 
In this study, MLC and couch tracking were found to significantly improve the geometrical and 
dosimetrical accuracy of hypo-fractionated prostate treatments, while couch tracking showed 
generally better performance than MLC tracking. Couch and MLC tracking are motion-
mitigation techniques which can be implemented at conventional linear accelerators accessible 
to a large cohort of patients. 
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Figure 1: A) Sections of prostate motion traces (Trace 1-5). B) Temporal fraction of 3D prostate 
displacement larger than 3, 5, 7 and 10 mm. C) Mean values of the 3D, LR, CC and AP 
displacement for each trace.  
 
 
Figure 2: Schematic workflow of geometrical evaluation: 1) The artificially enlarged VMAT 
plans are applied and measured with the MV imager. 2) The center of the lead sphere is 
identified on the moved and static images and the artificially enlarged area is removed after 
rotating of the image. 3) Binary images are created by applying a threshold. 4) Both images 
are aligned and substracted. 5) Over- and underexposed areas at the field edges are summed 
up.  
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Figure 3: Geometrical and dosimetrical evaluation: Results are shown as boxplots over all 
patients for each motion trace (1-5) and collimator rotation (0° with plain box left, 90° with 
shaded box right at each trace), and for all measurements combined (All). A) The mean over- 
and underexposed area (?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒) of all mitigation modes and of repeated static 
measurements of one patient pre- and post-acquisition (accuracy) B) The 2%/2-mm gamma 
agreement over the entire measurement phantom for doses larger than 20%. 
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Figure 4: Organ specific dosimetrical evaluation: Results are shown as boxplots over all 
patients, motion traces and collimator rotations combined for the three mitigation modes: no 
mitigation (left in each plot), MLC tracking (middle) and couch tracking (right). Gamma 
agreement indices (GAI) with 1%/1-mm and 2%/2-mm criteria are shown for all structures, 
changes in the mean dose (ΔDmean) and the dose to 95% (ΔD95) for the target structures, 
and changes in maximum dose (ΔDmax) for the organs at risk. Δ: moved-static.  
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Table 1: Geometrical and dosimetrical evaluation. Median and quartiles of the over-
/underexposed areas, gamma agreement indices and differences in dose parameters are 
given for each structure, showing the agreement with the static reference situation. Δ: 
moved-static. 
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Evaluation parameter Median (q25, q75) 
Median 
(q25, q75) 
Median 
(q25, q75) 
?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 (cm2) 
2.02 
(1.55, 2.51) 
1.00 
(0.77, 1.21) 
0.45 
(0.40, 0.54) 
Phantom    
 GAI 1%/1mm (%) 53.6 (47.6, 65.8) 
88.4 
(80.9, 92.0) 
99.2 
(96.0, 100.0) 
 GAI 2%/2mm (%) 83.9 (77.0, 94.1) 
98.6 
(96.3, 99.7) 
100.0 
(100.0, 100.0) 
Index lesion    
 GAI 1%/1mm (%) 88.5 (66.7, 100.0) 
100.0 
(85.1, 100.0) 
100.0 
(100.0, 100.0) 
 GAI 2%/2mm (%) 100.0 (99.8, 100.0) 
100.0 
(100.0, 100.0) 
100.0 
(100.0, 100.0) 
 ΔDmean (%) -0.64 (-1.69, 0.18) 
0.22 
(-0.20, 0.81) 
0.11 
(-0.21, 0.24) 
 ΔD95 (%) -1.28 (-2.79, -0.00) 
-0.05 
(-0.54, 0.80) 
-0.05 
(-0.45, 0.27) 
Prostate    
 GAI 1%/1mm (%) 76.0 (51.1, 86.4) 
88.2 
(77.6, 93.9) 
100.0 
(99.5, 100.0) 
 GAI 2%/2mm (%) 96.2 (77.4, 99.5) 
99.6 
(96.6, 100.0) 
100.0 
(100.0, 100.0) 
 ΔDmean (%) -0.17 (-0.95, 0.19) 
0.49 
(0.21, 0.81) 
0.09 
(-0.05, 0.28) 
 ΔD95 (%) -0.86 (-2.88, 0.18) 
0.32 
(-0.09, 0.72) 
0.05 
(-0.09, 0.24) 
Rectum    
 GAI 1%/1mm (%) 64.2 (47.3, 88.9) 
99.9 
(98.8, 100.0) 
100.0 
(100.0, 100.0) 
 GAI 2%/2mm (%) 97.0 (86.4, 100.0) 
100.0 
(100.0, 100.0) 
100.0 
(100.0, 100.0) 
 ΔDmax (%) 0.12 (-1.16, 1.99) 
0.32 
(-0.41, 1.03) 
0.23 
(-0.13, 0.65) 
Urethra    
 GAI 1%/1mm (%) 77.5 (59.6, 92.9) 
86.1 
(73.8, 96.7) 
100.0 
(100.0, 100.0) 
 GAI 2%/2mm (%) 97.7 (86.5, 100.0) 
100.0 
(97.5, 100.0) 
100.0 
(100.0, 100.0) 
 ΔDmax (%) 0.35 (-0.16, 1.40) 
1.05 
(0.36, 1.73) 
0.33 
(-0.00, 0.57) 
Bladder    
 GAI 1%/1mm (%) 76.8 (57.8, 87.7) 
99.3 
(97.0, 99.8) 
100.0 
(99.9, 100.0) 
 GAI 2%/2mm (%) 96.7 (90.7, 99.5) 
100.0 
(99.9, 100.0) 
100.0 
(100.0, 100.0) 
 ΔDmax (%) 0.04 (-1.38, 0.94) 
0.29 
(-0.32, 0.86) 
0.15 
(-0.14, 0.32) 
q25, q75: 25%- and 75%-percentiles 
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Table 2: Comparisons of motion mitigation modes with Friedman’s test followed by Wilcoxon 
sign rank tests, and Spearman correlations of dosimetrical and geometrical results. 
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Spearman correalation 
with ?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 
Evaluation parameter p-value+ p-value++ p-value++ p-value++ Rho p-value+++ 
?̅?𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 (cm2) <0.001 <0.001 <0.001 <0.001 - - 
Phantom       
 GAI 1%/1mm <0.001 <0.001 <0.001 <0.001 -0.85 <0.001 
 GAI 2%/2mm <0.001 <0.001 <0.001 <0.001 -0.87 <0.001 
Index lesion       
 GAI 1%/1mm <0.001 0.191 ns <0.001 <0.001 -0.64 <0.001 
 GAI 2%/2mm <0.001 1.000 ns <0.001 0.059 ns -0.43 <0.001 
 ΔDmean 0.002 <0.001 <0.001 0.049 -0.23 <0.001 
 ΔD95 <0.001 <0.001 <0.001 0.242 ns -0.24 <0.001 
Prostate       
 GAI 1%/1mm <0.001 <0.001 <0.001 <0.001 -0.85 <0.001 
 GAI 2%/2mm <0.001 <0.001 <0.001 <0.001 -0.84 <0.001 
 ΔDmean <0.001 <0.001 <0.001 <0.001 -0.17 0.057 ns 
 ΔD95 <0.001 <0.001 <0.001 0.005 -0.31 <0.001 
Rectum       
 GAI 1%/1mm <0.001 <0.001 <0.001 <0.001 -0.83 <0.001 
 GAI 2%/2mm <0.001 <0.001 <0.001 0.003 -0.71 <0.001 
 ΔDmax 1.000 ns 1.000 ns 1.000 ns 1.000 ns 0.18 0.044 
Urethra       
 GAI 1%/1mm <0.001 0.300 ns <0.001 <0.001 -0.78 <0.001 
 GAI 2%/2mm <0.001 0.463 ns <0.001 <0.001 -0.62 <0.001 
 ΔDmax <0.001 0.453 ns 1.000 ns <0.001 0.15 0.192 ns 
Bladder       
 GAI 1%/1mm <0.001 <0.001 <0.001 <0.001 -0.77 <0.001 
 GAI 2%/2mm <0.001 <0.001 <0.001 0.009 -0.77 <0.001 
 ΔDmax 0.615 ns 1.000 ns 1.000 ns 0.687 ns -0.06 1.000 ns 
ns: not significant 
p-values were adjusted according to Bonferroni correction (+/++/+++: multiplied by factor 20//60/19) 
Rho: Spearman correlation coefficient 
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Table 3: Comparisons of motion mitigation modes with Brown-Forsythe test for equal 
variance. 
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Evaluation parameter p-value+ p-value++ p-value++ p-value++ 
Index lesion     
 ΔDmean <0.001 <0.001 <0.001 <0.001 
 ΔD95 <0.001 0.051 ns <0.001 1.000 ns 
Prostate     
 ΔDmean <0.001 <0.001 <0.001 <0.001 
 ΔD95 <0.001 <0.001 <0.001 0.011 
Rectum     
 ΔDmax <0.001 <0.001 <0.001 <0.001 
Urethra     
 ΔDmax <0.001 0.196 ns <0.001 <0.001 
Bladder     
 ΔDmax <0.001 <0.001 <0.001 <0.001 
ns: not significant 
p-values were adjusted according to Bonferroni correction (+/++: multiplied by 
factor 7/21) 
 
 
